Agilent Technologies, Inc.

A · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$113K – $28K 6 disclosures · 3 bought / 3 sold · last May 18, 2026
Lamar Smith R · HOUSE · TX	$2K – $30K $5K – $81K today 2 filings · last May 16, 2018
Sheldon Whitehouse D · SENATE · RI	−$14K – $14K −$57K – $61K today 2 filings · last Feb 24, 2015
Lisa C. McClain R · HOUSE · MI	−$14K – $14K −$21K – $21K today 2 filings · last Jul 16, 2025
Tommy Tuberville R · SENATE · AL	−$28K – $28K −$39K – $35K today 4 filings · last May 3, 2024
Robert Bresnahan R · HOUSE · PA	−$14K – $14K −$25K – $21K today 2 filings · last May 15, 2025
Bob Corker R · HOUSE · TN	−$14K – $14K −$62K – $58K today 2 filings · last Feb 14, 2014
Peter Welch D · SENATE · VT	−$29K – $13K −$47K – $35K today 3 filings · last Nov 18, 2021
Julie Johnson D · HOUSE · TX	−$44K – $12K −$63K – $16K today 4 filings · last Sep 23, 2025
Jefferson Shreve R · HOUSE · IN	−$85K – $20K −$123K – $40K today 3 filings · last May 12, 2025

Recent transactions

Trades from Oct 31, 2023 – Sep 23, 2025

Politician	Type	Filed after	Amount
Julie Johnson D · HOUSE · TX-32	Sell	316 days Sep 23, 2025 → Aug 5, 2026	≥$1K
Julie Johnson D · HOUSE · TX-32	Buy	316 days Sep 23, 2025 → Aug 5, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	6 days Jun 30, 2026 → Jul 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	34 days Jun 2, 2026 → Jul 6, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	44 days May 18, 2026 → Jul 1, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	47 days Mar 27, 2026 → May 13, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	51 days Mar 23, 2026 → May 13, 2026	≥$15K
Donald Trump R · EXECUTIVE	Sell	56 days Mar 18, 2026 → May 13, 2026	≥$50K
Donald Trump R · EXECUTIVE	Sell	57 days Mar 17, 2026 → May 13, 2026	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,166

13F shares

263.9M

Total invested

$34.8B

Ownership

93.3%

New positions

148

Closed positions

Increased positions

606

Reduced positions

357

Put/Call ratio

0.90

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	25.6M	$3.4B	−1.17%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	18.4M	$2.5B	+0.37%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	14.4M	$1.9B	+0.63%
STATE STREET CORP	9/22/2026	12.9M	$1.7B	+0.70%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	8/3/2026	10M	$1.4B	−20.70%
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.	8/14/2026	7.8M	$1.0B	−13.74%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	7.6M	$1.0B	+0.98%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	7.5M	$990.2M	+2.73%
DEUTSCHE BANK AG\	8/7/2026	7M	$931.0M	+17.12%
BANK OF NEW YORK MELLON CORP	8/6/2026	5.2M	$695.2M	+87.36%
MORGAN STANLEY	8/13/2026	5.2M	$688.8M	+4.78%
FMR LLC	8/13/2026	5.1M	$674.3M	+453.68%
GOLDMAN SACHS GROUP INC	8/14/2026	4.7M	$625.3M	+31.59%
PICTET ASSET MANAGEMENT HOLDING SA	7/30/2026	4.5M	$597.0M	+28.51%
NORGES BANK	8/12/2026	3.9M	$514.0M	—
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	8/12/2026	3.8M	$508.1M	+0.00%
NORTHERN TRUST CORP	8/13/2026	3.7M	$490.4M	−0.22%
AQR CAPITAL MANAGEMENT LLC	8/14/2026	3.6M	$472.4M	+20.36%
INVESCO LTD.	8/14/2026	2.8M	$377.7M	+22.87%
TROY ASSET MANAGEMENT LTD	7/31/2026	2.7M	$355.5M	+10.92%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	2.5M	$338.0M	−3.84%
NORDEA INVESTMENT MANAGEMENT AB	8/5/2026	2.4M	$310.8M	+0.19%
JPMORGAN CHASE & CO	8/12/2026	2.3M	$306.8M	−0.52%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	2.3M	$306.4M	+9.38%
FIRST TRUST ADVISORS LP	8/11/2026	2.1M	$276.2M	+164.56%

Insider transactions

Insider	Type	Transacted	Price	Date
Boehnlein Glenn S	A-AWARD	817	$146.85	Sep 8
Dolsten Mikael	S-SALE	634	$151.38	Sep 4
Boehnlein Glenn S		0	—	Sep 4
Boehnlein Glenn S		0	—	Sep 4

Analyst consensus

Buy41 analysts

Bearish · 1 · Hold · 7 · Bullish · 33

Earnings history

	EPS	Estimate
Q4 2024	$1.46	$1.41	Beat
Q1 2025	$1.31	$1.28	Beat
Q2 2025	$1.31	$1.26	Beat
Q3 2025	$1.37	$1.37	Match
Q4 2025	$1.59	$1.58	Beat
Q1 2026	$1.36	$1.37	Miss
Q2 2026	$1.49	$1.41	Beat
Q3 2026	$1.62	$1.49	Beat

Peers

Company overview

IPO dateNov 18, 1999

CEOPadraig McDonnell

Employees18,200

SectorHealthcare

IndustryMedical - Diagnostics & Research

CountryUS

ExchangeNew York Stock Exchange

Websitewww.agilent.com

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.